SynthesisEuropean radiology2024
Quality assessment of the MRI-radiomics studies for MGMT promoter methylation prediction in glioma: a systematic review and meta-analysis.
Synthesis in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Pre-operative MRI-Based Radiomics for Predicting Telomerase Reverse Transcriptase Promoter Mutation Status in Glioma Patients: A Systematic Review and Meta-analysis.Neurosurgical review · 2026Pooled it
- Diagnostic performance of deep learning for predicting glioma isocitrate dehydrogenase and 1p/19q co-deletion in MRI: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Radiomics diagnostic performance for predicting lymph node metastasis in esophageal cancer: a systematic review and meta-analysis.BMC medical imaging · 2024Pooled it
- Article
- Why Radiomics Rarely Reaches the Clinic: Reproducibility, Validation, and Evidence Gap-A Critical Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes.Molecular biology reports · 2026Review
- AI-driven radiogenomics in gynecologic oncology: from radiological digital biopsy to a new paradigm in precision therapy.Frontiers in oncology · 2026Review
- Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.Frontiers in medicine · 2026Review
- Article
- Diagnostic Accuracy of Deep Learning Models in Predicting Glioma Molecular Markers: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Virtual Biopsy for the Prediction of MGMT Promoter Methylation in Gliomas: A Comprehensive Review of Radiomics and Deep Learning Approaches Applied to MRI.Diagnostics (Basel, Switzerland) · 2025Review
- Robust radiomics: a review of guidelines for radiomics in medical imaging.Frontiers in radiology · 2025Review
- Apparent diffusion coefficient predicts MGMT status in adult-type diffuse gliomas and is correlated with Ki-67 proliferation index.Frontiers in oncology · 2025Article
- Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study.Frontiers in oncology · 2025Article
- Multimodal MRI andDiagnostics (Basel, Switzerland) · 2024Article
- Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the methodological quality and diagnostic accuracy of MRI-based radiomic studies predicting O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in gliomas.
methodsPubMed Medline, EMBASE, and Web of Science were searched to identify MRI-based radiomic studies on MGMT methylation in gliomas published until December 31, 2022. Three raters evaluated the study methodological quality with Radiomics Quality Score (RQS, 16 components) and Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis Or Diagnosis (TRIPOD, 22 items) scales. Risk of bias and applicability concerns were assessed with QUADAS-2 tool. A meta-analysis was performed to estimate the pooled area under the curve (AUC) and to assess inter-study heterogeneity.
resultsWe included 26 studies, published from 2016. The median RQS total score was 8 out of 36 (22%, range 8-44%). Thirteen studies performed external validation. All studies reported AUC or accuracy, but only 4 (15%) performed calibration and decision curve analysis. No studies performed phantom analysis, cost-effectiveness analysis, and prospective validation. The overall TRIPOD adherence score was between 50% and 70% in 16 studies and below 50% in 10 studies. The pooled AUC was 0.78 (95% CI, 0.73-0.83, I
conclusionsStudy RQS and adherence to TRIPOD guidelines was generally low. Radiomic prediction of MGMT methylation status showed great heterogeneity of results and lower performances in grade IV gliomas, which hinders its current implementation in clinical practice. CLINICAL RELEVANCE STATEMENT: MGMT promoter methylation status appears to be variably correlated with MRI radiomic features; radiomic models are not sufficiently robust to be integrated into clinical practice to accurately predict MGMT promoter methylation status in patients with glioma before surgery. KEY POINTS: • Adherence to the indications of TRIPOD guidelines was generally low, as was RQS total score. • MGMT promoter methylation status prediction with MRI radiomic features provided heterogeneous diagnostic accuracy results across studies. • Studies that included grade IV glioma only and performed external validation had significantly lower diagnostic accuracy than others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.